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Abstract: Introduction: Pro-brain natriuretic peptide (Pro-BNP) can act as an independent predictor of mortality in septic
patients. This study aimed to compare the diagnostic accuracy of pro-BNP and Mortality in Emergency Depart-
ment Sepsis (MEDS) score in this regard. Methods: This cross-sectional study was conducted on > 14 years old
sepsis patients of an emergency department (ED), during 2 years. The level of Pro-BNP and MEDS score were
measured for all eligible patients and considering one month mortality as reference, screening performance
characteristics of the two tests were compared using SPSS 21 and STATS 11. Results: 121 patients with the mean
age of 75.87±11.82 years were studied (55.4% male). 85 (70.25%) patients had moderate to high probability
of mortality according to MEDS score. The mean Pro-BNP levels of survivor and non-survivor patients were
489.69 ± 327.47 and 3954.98 ± 2717.85 pg/ml, respectively (p < 0.0001). Sensitivity and specificity of Pro-BNP
(in 1000 pg/ml cut off) and MEDS score (in level 3) in prediction of 1-month mortality were 93.6 (83.7-97.9), 94.8
(84.7-98.6), 65.0 (51.9-76.3), and 98.2 (89.5-99.9), respectively. Area under the ROC curve of the two tests were
97.36 (95% CI: 92.92-94.48) and 92.31 (95% CI: 86.35-96.53), respectively (p = 0.0543). Conclusion: Pro-BNP and
MEDS score both have excellent diagnostic accuracy in predicting 1-month mortality of sepsis patients. How-
ever, considering the higher sensitivity as well as availability and ease of calculation, it seems that Pro-BNP can
be considered an appropriate tool for screening patients with high risk of mortality following sepsis in ED.
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1. Introduction
S
eptic response is in fact a chain of inflammatory and
anti-inflammatory processes and hormone-cell reac-
tions that manifest clinically via systemic disorders
such as: shock, myocardial disorder, activation of coagula-
tion system and disseminated endothelial injury (1-4). Based
on the report of world health organization (WHO), in United
States of America more than 1 million people are affected
with sepsis, about half of which lose their lives and sepsis
is the third cause of mortality after heart diseases and can-
cers (5, 6). Timely identification of patients at risk of mortal-
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ity due to sepsis can be helpful in selecting type of interven-
tion, treatment protocol, diagnostic method, and probably
improve their final outcome (7-9). Mortality in Emergency
Department Sepsis (MEDS) score is an acceptable scale for
predicting the prognosis of sepsis, which is not commonly
used nowadays due to having many variables and its calcula-
tion being time consuming (10). Currently, biomarkers such
as: Pro-BNP, lactate, CRP, D-Dimer, Pro-Calcitonin and Tro-
ponin are considered for determining the prognosis of pa-
tients with sepsis (11-13). Natriuretic peptides are used in
diagnosis and risk stratification of patients with acute coro-
nary syndrome and congestive heart failure but the role of
these factors in prognosis and diagnosis of patients with sep-
tic shock is still under debate (14). Natriuretic peptides play
an important role in maintenance of cardiovascular home-
ostasis and circulating blood volume. Pro-BNP is secreted in
response to stretching in the atrium or ventricle wall or due to
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myocardial ischemia in 2 shapes of N-terminal Pro-BNP (NT-
Pro BNP) and C-terminal peptide (BNP) (15, 16). It has been
shown that Pro-BNP can act as an independent predictor of
mortality in patients with cardiac shock, septic shock, and se-
vere sepsis (17-23). However, this marker has not been able to
predict short-term mortality in critically ill patients hospital-
ized in critical care unit with hypoxic respiratory failure (24).
Therefore, in search for finding an accurate as well as easy
and available scale for replacing MEDS score in emergency
department (ED), the present study was designed with the
aim of evaluating the diagnostic value of pro-BNP in compar-
ison with MEDS score in determining the prognosis of sepsis
patients ED.
2. Methods
2.1. Study design and setting
The present study is a prospective cross-sectional one that
was designed and performed with the aim of determining
the diagnostic accuracy of Pro-BNP in predicting the prog-
nosis of patients with sepsis in ED of Imam Hossein Hospi-
tal, Tehran, Iran, from September 2014 to March 2016. Pro-
tocol of this study was approved by the ethics committee of
Shahid Beheshti University of Medical Sciences and the re-
searchers adhered to the principles indicated in the declara-
tion of Helsinki regarding medical ethics. Before entering the
study, the patient or their relative signed an informed written
consent for participating in the study. The research team did
not interfere in the diagnostic and treatment processes of the
patients.
2.2. Participants
Patients over the age of 14 years with sepsis presenting to the
ED were randomly included in the study. For random sam-
pling, cases were selected on random days (these days were
randomly selected on the first day of each month). Simul-
taneous presence of systemic inflammatory response syn-
drome (SIRS) criteria and definitive evidence of infection
based on American College of Chest Physicians/Society of
Critical Care Medicine consensus was considered as the def-
inition of sepsis (25). Patients with diagnosis of sepsis, severe
sepsis, or septic shock were included in the study. Cases with
history of proven cardiac or kidney failure, electrocardiogram
(ECG) indicating new cardiac problems and children were ex-
cluded from the study.
2.3. Data gathering
Demographic data (age, sex), source of infection (pneumo-
nia; urinary tract infection; digestive disease; bedsore and
. . . ), variables needed for calculation of MEDS score (10),
serum level of Pro-BNP on admission as well as 1-month out-
come of the patients regarding mortality were gathered for
all the patients via a pre-designed checklist. Source of infec-
tion was determined according to the final decision of the in
charge physician and considering all the laboratory, imaging,
and clinical evidence. Pro-BNP measurement was done us-
ing 1cc of the patient’s venous blood sample drawn on ad-
mission for measuring other laboratory parameters ordered
by the in charge physician. Blood drawing was done by a lab-
oratory technician who was not aware of the study. Pro-BNP
level measurement was done via chemilumenescence sand-
wich immunoassay using Elecsys 2010 kit, Roche diagnostic,
Mannheim, Germany. The kit was a high-quality and rapid
(taking 18 minutes) kit that finally reports Pro-BNP rate as
pg/cc. To calculate MEDS score, a medical calculator named
emcalculator was used and according to the results the pa-
tients were divided into 5 groups regarding mortality risk:
very low, low, moderate, high, and very high. Finally, the mor-
tality status of the patients 30 days after admission to ED was
followed and recorded via phone calls. It should be noted
that treatment of sepsis patients in the mentioned center is
done according to the protocol of surviving sepsis campaign
by emergency service with consultation of infection service
(26). One emergency medicine resident was in charge of data
gathering, calculating MEDS score and follow up of patients
by phone.
2.4. Statistical Analysis
Minimum sample size required for the present study consid-
ering 95% confidence interval, 80% power, 7% error, and 0.63
area under the receiver operating characteristic (ROC) curve
of Pro-BNP (27), was calculated to be 122 cases. Data were
analyzed via SPSS 21 and STATA 11 software. Qualitative data
were reported as frequency and percentage, and quantitative
data as mean ± standard deviation (SD). Finally, for deter-
mining the diagnostic accuracy of Pro-BNP in predicting the
1-month prognosis of sepsis patients, ROC curve was drawn
and the best cut-off was calculated. In addition, sensitivity,
specificity, positive and negative predictive values, and pos-
itive and negative likelihood ratios with 95% confidence in-
terval were calculated and reported using VassarStats medi-
cal calculator. To compare the diagnostic accuracies of the 2
tests in predicting the risk of 1-month mortality in patients
with sepsis presenting to the ED, comparison of area under
the ROC curve was done via chi square test. In all analy-
ses p<0.05 was considered as level of significance. Accuracy
of 0.90-0.100 was considered as excellent, 0.80-0.90 as good,
0.70-0.80 as fair, 0.60-0.70 as poor, and 0.50-.60 as fail.
3. Results
3.1. Baseline characteristics
155 patients were candidates for entering the study, 9 (5.80%)
were excluded due to history of kidney failure and 7 (4.52%)
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Figure 1: Mean and standard deviation of patients’ Pro-BNP level
based on their MEDS score level.
Figure 2: Area under the receiver operating characteristic (ROC)
curve of Pro-BNP and MEDS score in determining the risk of 1-
month mortality among sepsis patients in emergency department
(p=0.0543).
due to cardiac failure. In addition, 18 (11.61%) were excluded
due to missing data and problem in follow-up. Finally, 121
patients with the mean age of 75.87±11.82 (20-98) years were
evaluated (55.4% male). Table 1 shows the baseline char-
acteristics of the patients. 85 (70.25%) patients had moder-
ate to high probability of mortality according to MEDS scale.
The mean Pro-BNP levels of survivor and non-survivor pa-
tients were 489.69 ± 327.47 and 3954.98 ± 2717.85 pg/ml, re-
spectively (p < 0.0001). Figure 1 depicts mean Pro-BNP level
based on the patients’ MEDS score.
3.2. Screening performance characteristics
Of all the studied patients, 63 (52.1%) died after 1 month.
Area under the ROC curve of Pro-BNP and MEDS score in
prediction of 1-month mortality of sepsis patients admitted
to ED were 97.36 (95% CI: 92.92-94.48) and 92.31 (95% CI:
86.35-96.53), respectively (p = 0.0543, figure 2). According to
the area under the ROC curve, the best cut off to predict 1-
month mortality was 1000 pg/ml for Pro-BNP and level 3 for






20 - 40 3 (2.5)
40 - 60 7 (5.8)
≥ 60 111 (91.7)
Source of infection
Pneumonia 49 (40.5)
Urinary tract infection 45 (37.2)
Digestive problem 14 (11.6)
Bedsore 6 (4.9)








< 1000 59 (48.8)
≥ 1000 62 (51.2)
Data are reported as frequency and percentage.
MEDS scale. Table 2 shows the screening performance char-
acteristics of MEDS score and Pro-BNP in the mentioned cut
offs.
3.3. Discussion:
Based on the findings of the present study, Pro-BNP over
1000 pg/ml and MEDS scale both have excellent diagnostic
accuracy in predicting 1-month mortality of sepsis patients.
However, considering the higher sensitivity of Pro-BNP (93.6
vs. 65.0) as well as availability and ease of calculation, it
seems that Pro-BNP can be considered an appropriate tool
for screening patients with high risk of mortality following
sepsis in ED. Presently, various tools have received attention
for determining the prognosis of critically ill patients (26, 28,
29). In a study by Varpula et al. in 2007, it was shown that
Pro-BNP changes in the first 3 days of hospitalization is a
good prognostic scale in septic patients (19). In Kimmoun
et al. study in 2013 Pro-BNP level directly correlated with the
hemodynamic changes of septic patients (30). A comparison
regarding increase in Pro-BNP among cardiac patients and
sepsis patients showed a significant increase in the level of
this marker in sepsis or septic shock patients compared to
cardiac patients (31). In Carpenter et al. study, it was shown
that 44% of those with sepsis or septic shock have levels of
systolic disorders and in line with this finding they deemed
higher serum BNP levels in these patients associated with
worse outcome (32). Another study has also suggested the
concentration of this biomarker on the 5th day after hospi-
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Table 2: Screening performance characteristics of Pro-BNP in 1000 pg/ml cut-off and MEDS score in level 3 (moderate to high risk of death)
Characteristics Pro-BNP MEDS
True positive 59 41
True negative 55 57
False positive 3 1
False negative 4 22
Sensitivity 93.6 (83.7-97.9) 65.0 (51.9-76.3)
Specificity 94.8 (84.7-98.6) 98.2 (89.5-99.9)
Positive predictive value 95.2 (85.6-98.7) 97.6 (85.9-99.8)
Negative predictive value 93.2 (82.7-97.8) 72.2 (60.8-81.4)
Positive likelihood ratio 19.66 (6.51-59. 3) 41.0 (5.9-284. 4)
Negative likelihood ratio 0.07 (0.02-0.18) 0.3 (0.2-0. 5)
Measures are presented with 95% confidence interval.
talization as an index for prognosis of critically ill patients
with a higher risk of mortality (33). On the other hand, ac-
curacy of MEDS score in prediction of 1-month risk of mor-
tality for sepsis patients has been evaluated and declared in
numerous studies. Kuo et al. studied 431 patients with pyo-
genic liver abscesses and affirmed the high accuracy of this
scale in this regard (34). Another study in 2003 introduced
this scale as a proper tool for triage and making decisions re-
garding treatment of sepsis patients (10). A study in Nether-
lands in 2012 indicated the higher power of this scale com-
pared to biomarkers such as CRP and Lactate in prediction
of 28-day mortality of sepsis patients in ED (35). Area under
the ROC curve of MEDS score in this regard was estimated to
be 0.81 in a study by Macdonald et al. (36). Considering all
the mentioned points as well as some other important points
including ease of calculation, availability, higher sensitivity,
and similar accuracy and specificity it seems that Pro-BNP
can be considered a more beneficial tool compared to MEDS
score in prediction of mortality risk and screening of patients
with sepsis in ED. It is obvious that doing this screening can
help in concentrating the treatment system on more critically
ill patients and using more rigorous diagnostic and treatment
modalities in trying for improving their outcome. However,
it should be noted that in developing countries such as Iran
Pro-BNP measurement is still expensive and it might appear
not cost effective to do this evaluation for all sepsis patients.
Yet it should be taken into account that proper allocation of
funds leads to overall decrease in treatment costs and im-
provement of patients’ outcome.
3.4. Limitations
Not differentiating the patients with sepsis, severe sepsis, and
septic shock can be one of the limitations of this study. It
might have been better to differentiate these patients and
evaluate the diagnostic accuracy of the tests in each of the
3 groups to improve the overall accuracy of the study.
4. Conclusion
Based on the findings of the present study, Pro-BNP and
MEDS score both have excellent diagnostic accuracy in pre-
dicting 1-month mortality of sepsis patients. However, con-
sidering the higher sensitivity as well as availability and ease
of calculation, it seems that Pro-BNP can be considered an
appropriate tool for screening patients with high risk of mor-
tality following sepsis in ED.
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